title: Closing the personalized medicine information gap: HER2 test documentation practice.
abstract: Uncertainty about human epidermal growth factor receptor-2 (HER2) testing practice in Canada continues to hinder efforts to improve personalized medicine. Pathologists routinely perform HER2 assessment for all tumors > 1 cm, and pathology is reported centrally to the provincial cancer registry.
  
  
  
  To understand patterns of HER2 test documentation for early-stage breast cancer (BC) patients in Ontario's centralized pathology reporting system.
  
  
  
  Retrospective cohort study of central HER2 test documentation in early-stage BC patients diagnosed in 2006-2007.
  
  
  
  Cohort and staging information was derived from cancer registry and admissions data. Linkage across administrative databases provided data on surgical and radiologic treatment, sociodemographic factors, diagnosis setting, and comorbidities. Pathology reports from the provincial cancer registry were reviewed for HER2 testing, hormone receptor, and grade. Unadjusted and adjusted odds ratios were calculated to determine factors related to HER2 documentation.
  
  
  
  A HER2 test was documented for 66% of 13,396 patients. HER2 documentation was associated with stage, hormone receptor, and tumor grade documentation. Higher stage and grade at diagnosis were also associated with HER2 documentation. All models suggested variable regional documentation patterns. Documentation did not differ by sociodemographic factors, presence of comorbidities, or surgical procedure.
  
  
  
  Despite a universal testing policy, the rate of centralized HER2 test documentation was lower than expected and related to disease severity. Differences in regional reporting likely reflect ascertainment bias inherent to centralized pathology reporting rather than testing access. Improved HER2 reporting is encouraged for cancer registration, quality-of-care measurement, and program evaluation.
authors: Centre for Evaluation of Medicines, St. Joseph’s Healthcare Hamilton, Hamilton, Ontario, Canada.
authors: Ilia L
authors: IL
authors: Ferrusi
authors: Craig C
authors: CC
authors: Earle
authors: Maureen
authors: M
authors: Trudeau
authors: Natasha B
authors: NB
authors: Leighl
authors: Eleanor
authors: E
authors: Pullenayegum
authors: Hoa
authors: H
authors: Khong
authors: Jeffrey S
authors: JS
authors: Hoch
authors: Deborah A
authors: DA
authors: Marshall
mesh_terms: D001943:Breast Neoplasms / Q000175:diagnosis / Q000235:genetics*; D005260:Female; D005820:Genetic Testing / Q000706:statistics & numerical data*; D006801:Humans; D009864:Ontario; D057285:Precision Medicine / Q000706:statistics & numerical data*; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000235:genetics*; D012189:Retrospective Studies
chemical_list: D018719:Erb-b2 Receptor Tyrosine Kinases; C508053:ERBB2 protein, human
references: Science. 1987 Jan 9;235(4785):177-82
references: 3798106
references: Clin Oncol (R Coll Radiol). 2010 Dec;22(10):894
references: 20708911
references: J Clin Oncol. 2004 Mar 1;22(5):854-63
references: 14990641
references: Public Health Genomics. 2012;15(1):1-10
references: 21540562
references: Science. 1989 May 12;244(4905):707-12
references: 2470152
references: Arch Pathol Lab Med. 2009 Oct;133(10):1515-38
references: 19792042
references: Breast Cancer Res. 2004;6(6):229-39
references: 15535852
references: Curr Opin Mol Ther. 2008 Jun;10(3):260-6
references: 18535933
references: Arch Pathol Lab Med. 2008 Jan;132(1):61-5
references: 18181675
references: J Oncol Pract. 2011 May;7(3 Suppl):e1s-7s
references: 21886507
references: BMC Health Serv Res. 2011 Jun 10;11:146
references: 21663672
references: Curr Oncol. 2007 Aug;14(4):149-53
references: 17710207
references: J Clin Epidemiol. 2004 Dec;57(12):1288-94
references: 15617955
references: Oncologist. 2008 Jun;13(6):620-30
references: 18586917
references: Med Care. 2005 Nov;43(11):1130-9
references: 16224307
references: J Clin Oncol. 2007 Jan 1;25(1):118-45
references: 17159189
references: Ann Oncol. 2008 Mar;19(3):487-95
references: 18065409
references: J Clin Oncol. 2011 Sep 1;29(25):3366-73
references: 21768458
references: CMAJ. 2007 May 8;176(10):1429-34
references: 17485695